Abstract
The treatment of HIV-related lymphomas is evolving in the era of HAART. Standard-dose chemotherapy and dose-intensive therapies appear to be feasible. Whether outcomes are improved with combination chemotherapy and HAART remains unclear. Efforts aimed at developing pathogenic-based therapies will continue as the mechanisms of HIV lymphomagenesis are elucidated.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Antiretroviral Therapy, Highly Active
-
Disease Management
-
Humans
-
Lymphoma, AIDS-Related / classification
-
Lymphoma, AIDS-Related / drug therapy*
-
Lymphoma, AIDS-Related / etiology*
-
Lymphoma, Non-Hodgkin
-
Salvage Therapy